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Abstract: Alpha(α)-thalassemia is a blood disorder caused by many types of inheritable α-globin
gene mutations which causes no-to-severe clinical symptoms, such as Hb Bart’s hydrops fetalis that
leads to early foetal death. Therefore, the aim of this meta-analysis was to provide an update from
year 2010 to 2020 on the prevalence of α-thalassemia in Southeast Asia. A systematic literature search
was performed using PubMed and SCOPUS databases for related studies published from 2010 to
2020, based on specified inclusion and exclusion criteria. Heterogeneity of included studies was
examined with the I2 index and Q-test. Funnel plots and Egger’s tests were performed in order
to determine publication bias in this meta-analysis. Twenty-nine studies with 83,674 subjects were
included and pooled prevalence rates in this meta-analysis were calculated using random effect
models based on high observed heterogeneity (I2 > 99.5, p-value < 0.1). Overall, the prevalence
of α-thalassemia is 22.6%. The highest α-thalassemia prevalence was observed in Vietnam (51.5%)
followed by Cambodia (39.5%), Laos (26.8%), Thailand (20.1%), and Malaysia (17.3%). No publication
bias was detected. Conclusions: This meta-analysis suggested that a high prevalence of α-thalassemia
occurred in selected Southeast Asia countries. This meta-analysis data are useful for designing
thalassemia screening programs and improve the disease management.
Keywords: prevalence; α-thalassemia; Southeast Asia; meta-analysis; haematological disorder
1. Introduction
Thalassemia is the most common hereditary red blood cell disorder which causes anemias due
to defective genes that code for globin proteins synthesis [1]. The inheritance of the thalassemia
genotype could result in the individual being either a carrier or a patient. There are two major types of
thalassemia: (1) alpha (α) and (2) beta (β), in which the former is the most common form of thalassemia
worldwide especially in Southeast Asia populations [2,3]. Both α- and β-thalassemia arise from genetic
defects in α and/or β-globin genes, which regulate the number of globin chains in red blood cells.
Genetic defects in either α and/or β-globin genes can cause imbalance in numbers of α and β chains in
red blood cells. This leads to the manifestation of clinical conditions known as α- or β-thalassemia.
The most common genetic defect in α-thalassemia is a deletion in the α-globin gene involving one or
both globin genes such as -α3.7, -α4.2, –SEA, –THAI, -αCD59, -α20.5, -αIVS I-1 and others (Figure 1) [4–6].
A highly severe form of deletional α-thalassemia, known as Haemoglobin (Hb) Bart’s hydrops fetalis,
is a homozygous α0-thalassemia deletion with a complete loss of functional α-globin that leads to
foetal death or death shortly after birth. Currently, there is no effective treatment for this disease [7,8].
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Figure 1. Some common changes in α-thalassemia in Southeast Asia. The genes are shown in boxes 
with a scale in kilobases (kb). The most common deletions of α-thalassemia mutations are indicated 
by grey bars indicating the length of deletion. (Adapted from Farashi & Harteveld, 2018 [6]) 
There are also cases of non-deletional mutations in the α-globin gene such as Hb Constant Spring 
(CS), which is caused by a nucleotide substitution in the termination codon TAA→CAA and also Hb 
Pakse (-α4PS), which is caused by the termination codon (UAA→CAA). This results in the elongation 
of the α-globin chain protein and causes severe anemia with serious complications that include liver 
impairment, cardiac disease and endocrine disorder [9,10]. Some cases of Hb CS require red blood 
cell transfusions when Hb drop to dangerously low levels [11]. Most importantly, an individual can 
carry a single or multiple type form of the mutation (deletional/non-deletional), which give rise to 
different clinical manifestations and complicates diagnosis as well as treatments for α-thalassemia 
[12]. Both deletional and non-deletional α-thalassemia prevalence rates are highly important in 
determining the overall severity of clinical symptoms in a region or a specific population. 
Despite the detrimental effects of thalassemia, evidence shows that thalassemia confers a 
protective effect against hyperparasitemia due to malaria infection [13]. Plasmodium vivax parasitemia 
were two to three times lower in thalassemia patients as compared to malaria cases in people without 
thalassemia. However, the protective effect of thalassemia against parasitemia was not observed in a 
study conducted in Papua New Guinea in children aged 3–21 months [14]. Therefore, there is a 
natural selection force which leads to the prevalence of thalassemia cases in malaria-endemic areas 
[15]. 
Most of the α-thalassemia cases reveal some abnormalities in their red cell index. According to 
the British Committee for Standards in Haematology, a value of <27 pg in the average amount of Hb 
found in red blood cells (also referred as Mean Corpuscular Hemoglobin) is the primary screening 
threshold to quantify Hb subtypes [16]. However, subjects with a single gene deletion or carriers of 
the mutation in the non-severe form of α-thalassemia may present a normal Hb level. Different 
heterozygosity or homozygosity of gene deletions or mutations in the α-thalassemia gene gives 
different phenotypes, which complicates treatment [12]. Therefore, diagnosing of non-severe forms 
of α-thalassemia is a highly challenging task. 
Several countries in the Southeast Asia region have reported the prevalence of α-thalassemia in 
different ethnic groups independently, revealing that the prevalence of α-thalassemia differs from 
country to country with different ethnicities [4,5,17,18]. However, no studies have systematically 
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There are also cases of non-deletional utations in the α-globin gene such as Hb Constant Spring
(CS), which is caused by a nucleotide substitution in the termination codon TAA→CAA and also Hb
Pakse (-α4PS), which is caused by the termination codon (UAA→CAA). This results in the elongation
of the α-globin chain protein and causes severe anemia with serious complications that include liver
impairment, cardiac disease and endocrine disorder [9,10]. Some cases of Hb CS require red blood
cell transfusions when Hb drop to dangerously low levels [11]. Most importantly, an individual can
carry a single or multiple type form of the mutation (deletional/non-deletional), which give rise to
different clinical manifestations and complicates diagnosis as well as treatments for α-thalassemia [12].
Both deletional and non-deletional α-thalassemia prevalence rates are highly important in determining
the overall severity of clinical symptoms in a region or a specific population.
Despite the detrimental effects of thalassemia, evidence shows that thalassemia confers a protective
effect against hyperparasitemia due to malaria infection [13]. Plasmodium vivax parasitemia were
two to three times lower in thalassemia patients as compared to malaria cases in people without
thalassemia. However, the protective effect of thalassemia against parasitemia was not observed in a
study conducted in Papua New Guinea in children aged 3–21 months [14]. Therefore, there is a natural
selection force which leads to the prevalence of thalassemia cases in malaria-endemic areas [15].
Most of the α-thalassemia cases reveal some abnormalities in their red cell index. According to the
British Committee for Standards in Haematology, a value of <27 pg in the average amount of Hb found
in red blood cells (also referred as Mean Corpuscular Hemoglobin) is the primary screening threshold
to quantify Hb subtypes [16]. However, subjects with a single gene deletion or carriers of the mutation
in the non-severe form of α-thalasse ia may present a normal Hb level. Different heterozygosity or
homozygosity of gene deleti ns or mutations in the α-thalassemia gen gives diff rent phenotypes,
which complicates treatment [12]. Therefore, diagnosing of non-severe f rms f α-thalass mia i a
highly challenging t sk.
Several countries i t east Asia region have reported the prevalence of α-thalassemia
in different ethnic groups independently, revealing tha the prevalence of α-thalassemia differs from
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country to country with different ethnicities [4,5,17,18]. However, no studies have systematically
meta-analyzed the prevalence and epidemiology of α-thalassemia—where the results of these similar
studies are quantitatively combined—for this region. Therefore, the aim of this meta-analysis was to
provide an update (from 2010 until 2020) using data concerning α-thalassemia prevalence in Southeast
Asia, focusing on Cambodia, Laos, Malaysia, Thailand, and Vietnam. The study outcome on the
perspective of α-thalassemia prevalence in Southeast Asia could aid in designing healthcare policies
for α-thalassemia screening in large populations and provide better genetic counselling programs.
2. Materials and Methods
2.1. Study Guidelines and Literature Search
PRISMA guidelines were followed for conducting and reporting the results of this meta-analysis
(Table S1) [19]. PubMed (Table S2) and SCOPUS (Table S3) databases were searched up to March 2020
with the lower limit set to January 2010 using related terms, including alpha, thalassemia, southeast,
and Asian.
2.2. Selection of Studies and Data Extraction
All search results were screened by two investigators, and all potential studies were independently
reviewed to be included in this meta-analysis. The main inclusion criteria were: (1) studies published
in English in which the prevalence of α-thalassemia (including all deletional and non-deletional
mutations) in Southeast Asian countries were reported; and (2) the study was a peer-reviewed
publication. Studies that did not report cross-sectional, observational, cohort, or prevalence of
α-thalassemia were excluded. We identified additional eligible studies based on references that were
cited in the relevant articles. When publications overlapped, only the study with the largest or the most
recent data was included in this meta-analysis. Data, including first author’s name, publication year,
country, sample size, and prevalence of α-thalassemia of the included studies, were extracted and
documented by the reviewing investigators. A total number of 278 articles were included in this
meta-analysis (Tables S4 and S5). The study selection and review process are illustrated in Figure 2.
Int. J. Environ. Res. Public Health 2020, 17, x 3 of 13 
 
meta-analyzed the prevalence and epidemiology of α-thalassemia—where the results of these similar 
st dies are quantitatively combined—for this region. Therefore, the aim of this meta-analysis was to 
provide an update (from 2010 until 2020) using data concerning α-thalassemia prevalence in 
Southeast Asia, focusing on Cambodia, Laos, Malaysia, Thailand, and Vietnam. The study outcome 
on the perspective of α-thalassemia prevalence in S utheast Asia could aid in designing healt care 
policies for α-thalassemia screening in large populations and provide better genetic counselling 
programs. 
2. Materials and Methods  
2.1. Study Guidelines and Literature Search 
PRISMA guidelines were followed for conducting and reporting the results of this meta-analysis 
(Table S1) [19]. PubMed (Table S2) and SCOPUS (Table S3) databases were searched up to March 
2020 with the lower limit set to January 2010 using related terms, including alpha, thalassemia, 
southeast, and Asian. 
2.2. Selection of Studies and Data Extraction 
All search results were screened by two investigators, and all potential studies were 
independently reviewed to be included in this meta-analysis. The main inclusion criteria were: (1) 
studies published in English in which the prevalence of α-thalassemia (including all deletional and 
non-deletional mutations) in Southeast Asian countries were reported; and (2) the study was a peer-
reviewed publication. Studies that did not report cross-sectional, observational, cohort, or prevalence 
of α-thalassemia were excluded. We identified additional eligible studies based on references that 
were cited in the relevant articles. When publications overlapped, only the study with the largest or 
the most recent data was included in this meta-analysis. Data, including first author’s name, 
publication year, country, sample size, and prevalence of α-thalassemia of the included studies, were 
extracted and documented by the reviewing investigators. A total number of 278 articles were 
included in this meta-analysis (Tables S4 and S5). The study selection and review process are 
illustrated in Figure 2. 
 
Figure 2. Flow diagram of the systemic literature search in this study. Figure 2. Flo diagra of the syste ic literature search in this study.
Int. J. Environ. Res. Public Health 2020, 17, 7354 4 of 11
2.3. Statistical Analyses
The prevalence of α-thalassemia was calculated for each study with the number of reported
α-thalassemia cases as the numerator and the total sample size as the denominator. Homogeneity
across studies was investigated with the I2 index (represented as percentage) and Q-test (represented
as a p-value) that indicated heterogeneity between studies. It was reported that an I2 value > 75% and
Q-test with a p-value < 0.1 was regarded as high heterogeneity [20,21]. A random effects model was
used to combine individual effect sizes to create pooled α-thalassemia prevalence if a significantly high
heterogeneity was observed. If other results were obtained, a fixed effects model was utilized. A forest
plot was generated to illustrate the prevalence of each study with a 95% confidence interval (95% CI)
that contributed to the analysis along with the combined prevalence rate. A subsequent meta-analysis
was also performed based on each respective country. Funnel plots and Egger’s tests of asymmetry
were performed to identify any bias within the results [22,23]. All analyses were performed with
Comprehensive Meta-Analysis version 2 software (Biostat, Inc., New Jersey, USA) [24].
3. Results
3.1. Study Characteristics
Twenty-nine studies with a total number of 83,674 subjects were included in this meta-analysis after
a detailed assessment of records obtained from the database and additional searching. These studies
were published between January 2010 and October 2019. Among all included studies, two were carried
out in Cambodia, three in Laos, five in Malaysia, 20 in Thailand, and two in Vietnam (Table 1). The main
characteristics of the studies included in the meta-analysis were recorded and are shown in Table 1.
Table 1. Characteristics of studies included in the meta-analysis.
Author [Reference] α-ThalassemiaGenotyping Method
Genotypes Found in
the Study Country Specific Ethnic





3.7, -α4.2, –SEA, αCS, αPs Cambodia N/A 646 1631
Jomoui et al.,
2017 [26] PCR –
SEA Cambodia N/A 7 21
Wongprachum et al.,
2012 [27] PCR
-α3.7, -α4.2, –SEA, –THAI,
αCS, αPs, αQ-Thailand
Laos N/A 130 411
Jomoui et al.,
2017 [26] PCR –
SEA Laos N/A 28 52
Tritipsombut et al.,
2012 [28] PCR -α
3.7, -α4.2, –SEA, αCS, αPs Laos N/A 30 349
Azma et al.,
2012 [29] PCR Malaysia N/A 14 400
Azma et al., 2014 [4] PCR -α
3.7, -α4.2, –SEA, αCS,
αCD59, αIVS I-1
Malaysia Malay, Chinese,Indian, Other 736 1623
Jameela et al.,
2011 [30] PCR -α
3.7, -α4.2, –SEA, –FIL, α125 Malaysia
Malay, Chinese, Indian,
Sikh, Iban 10 310
Mohd Yatim et al.,
2014 [31] PCR -α
3.7, –SEA, αCS, αCD59, Malaysia Malay 28 68
Tan et al., 2010 [3] PCR -α
3.7, -α4.2, –SEA, –THAI,
–FIL, αCS, α125,





Thailand N/A 142 566
Lithanatudom et al.,
2016 [17] PCR
-α3.7, -α4.2, –SEA, –THAI,
αCS, αPs
Thailand





2012 [33] PCR -α
3.7, –SEA, αCS, αPs Thailand N/A 47 266
Pongjantharasatien
et al., 2016 [34] PCR –
SEA, –THAI, –FIL, -αthal-1 Thailand N/A 4555 31,632
Pichanun et al.,
2010 [35] PCR -α
3.7, αCS, αPs Thailand N/A 36 587
Pharephan et al.,
2016 [36] PCR -α
3.7, -α4.2, –SEA, αCS Thailand N/A 229 638
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Table 1. Cont.
Author [Reference] α-ThalassemiaGenotyping Method
Genotypes Found in
the Study Country Specific Ethnic
1 Events 2 Total 3
Panyasai et al.,
2016 [37] PCR -α
3.7, -αQT, –SEA, Thailand N/A 51 23,914
Panomai et al.,
2010 [38] PCR
-α3.7, -α4.2, –SEA, –THAI,
αCS, αPs





Thailand N/A 75 300
Seeratanachot et al.,
2015 [40] Realtime-PCR -α
3.7, -α4.2, –SEA Thailand N/A 62 250
Wisedpanichkij et al.,
2015 [41] PCR -α
3.7, -α4.2, –SEA, αCS Thailand N/A 409 578
Uaprasert et al.,
2013 [42] PCR -α
3.7, -α4.2, αCS Thailand N/A 67 241
Srivorakun et al.,
2011 [43] PCR -α
3.7, –SEA, αCS Thailand N/A 44 226
Tritipsombut et al.,
2012 [28] PCR -α
3.7, -α4.2, –SEA, αCS, αPs Thailand N/A 85 1460
Chaibunruang et al.,
2013 [44] PCR –
SEA, –THAI Thailand N/A 1874 12,525
Kulaphisit et al.,
2017 [5] PCR
-α3.7, -α4.2, –SEA, –THAI,
αCS αPs
Thailand
Yong, Lue, Yuan, Shan,
Khuen, Htin, Paluang,





al., 2019 [45] PCR -α
3.7, -α4.2, αCS, αPs Thailand N/A 676 1192
Jomoui et al.,
2017 [26] PCR –
SEA Thailand N/A 66 96
Mankhenthong et al.,
2019 [46] PCR
-α3.7, -α4.2, –SEA, –THAI,
αCS
Thailand N/A 118 1290
Pata et al., 2019 [47] PCR -α
3.7, -α4.2, –SEA, –THAI,
αCS
Thailand N/A 82 195
O’Riordan et al.,
2010 [18] PCR
-α3.7, -α4.2, –SEA, –THAI,
–FIL, αCS
Vietnam
Kinh, Dao, Tay, Nung,
S’Tieng, M’Nong, Rac Iay,
E De
996 1431
Hoa Nguyen et al.,
2014 [48] PCR
-α3.7, -α4.2, –SEA, –THAI,
–SEA, αCS, αPs
Vietnam Có-Tu 98 298
Total 11,580 83,674
1 N/A: Not available due to ethnicities were not reported by the study. 2 Events: Number of subjects carrying
alpha-thalassemia. 3 Total: Total number of subjects.
3.2. Meta-Analysis Outcomes
The meta-analysis was conducted using a random effects model found significant heterogeneity
showed an I2 > 99.5% and p-value < 0.001 in overall and all subgroups except Cambodia (Table 2).
The forest plot showed that the overall prevalence rate of α-thalassemia occurrence in this meta-analysis
was 0.226 (95% CI = 0.168–0.296; I2 = 99.5%; p-value < 0.1) (Figure 3). In the subgroup analysis based
on country, Vietnam had the highest prevalence rate (51.5%) of α-thalassemia followed by Cambodia
(39.5%) Laos (26.8%), Thailand (20.1%), and Malaysia (17.3%) (Figure 4).
Table 2. Prevalence rate and heterogeneity of α-thalassemia in overall and subgroups of the study.
Heterogeneity
Prevalence Rate (95% CI) Sample Size (N) No. of Studies (N) Subgroups
I2 (%) p-Value
99.53 <0.001 0.226 (0.168–0.296) 83,674 32 Overall
0 0.560 0.395 (0.372–0.419) 1652 2 Cambodia
97.26 <0.001 0.268 (0.096–0.559) 812 3 Laos
98.20 <0.001 0.173 (0.060–0.407) 2526 5 Malaysia
99.47 <0.001 0.201 (0.143–0.273) 76,955 20 Thailand
99.22 <0.001 0.515 (0.190–0.828) 1729 2 Vietnam
Int. J. Environ. Res. Public Health 2020, 17, 7354 6 of 11
Int. J. Environ. Res. Public Health 2020, 17, x 6 of 13 
 
Table 2. Prevalence rate and heterogeneity of α-thalassemia in overall and subgroups of the study. 
Heterogeneity 










99.53 <0.001 0.226 (0.168–0.296) 83,674 32 Overall 
0 0.560 0.395 (0.372–0.419) 1652 2 Cambodia 
97.26 <0.001 0.268 (0.096–0.559) 812 3 Laos 
98.20 <0.001 0.173 (0.060–0.407) 2526 5 Malaysia 
99.47 <0.001 0.2 1 (0.14 –0.273) 76,955 20 Thailand 
99.22 <0.001 0.515 (0.190–0.828) 1729 2 Vietnam 
 
Figure 3. Forest plot of α-thalassemia overall prevalence using random effects model. Figure 3. r st l t f -t l i ll l si g rando effects odel.Int. J. Environ. Res. Public Health 2020, 17, x 7 of 13 
 
 
Figure 4. Forest plot of the α-thalassemia prevalence grouped according to country. Figure 4. Forest plot of t l i l ro ped according to country.
Int. J. Environ. Res. Public Health 2020, 17, 7354 7 of 11
3.3. Publication Bias
Funnel plots and Egger’s tests were performed to estimate the publication bias of the included
literature. The shape of the funnel plot revealed obvious evidence of symmetry (Figure 5). The value
for Egger’s test was t-value = 1.24 with a p-value = 0.112.
Int. J. Environ. Res. Public Health 2020, 17, x 8 of 13 
 
3.3. Publication Bias 
Funnel plots and Egger’s tests were performed to estimate the publication bias of the included 
literature. The shape of the funnel plot revealed obvious evidence of symmetry (Figure 5). The value 
for Egger’s test was t-value = 1.24 with a p-value = 0.112. 
 
Figure 5. Funnel plot of the overall prevalence of α-thalassemia in this study. 
4. Discussion 
This study is the first to report the prevalence of α-thalassemia in the Southeast Asia region over 
the past 10 years (2010–2020). We did not obtain any α-thalassemia-related studies that fulfilled our 
inclusion and exclusion criteria from other Southeast Asian countries, including Brunei, Indonesia, 
Myanmar, Philippines, Singapore, and Timor-Leste. Using a random effects model, the overall 
prevalence rate of α-thalassemia in the included countries was 22.6%, which indicated a significant 
reduction of ~50% of the prevalence in the Southeast Asia region since 2008. The World Health 
Organization had reported the α-thalassemia prevalence as 44.6% in 2008 [49]. India and Brazil, were 
reported at about 12% and 19.2%, respectively [50,51]. The prevalence rates were high in countries 
such as UAE, Oman and Saudi Arabia at 50% [52]. 
The high prevalence of α-thalassemia in the past was due to the lack of knowledge regarding 
the seriousness of this disease among the populations in these countries, especially those living in 
rural areas with limited access to education and those who could not afford to obtain the proper 
education similar to that found in urban areas. α-thalassemia is an inherited disease and the 
mutations may pass from parent to child, affecting the haemoglobin production. Hence, the 
educational and screening campaigns regarding this disease conducted by the representative bodies 
(either government or non-government organization) have successfully reduced the prevalence of α-
thalassemia in the Southeast Asia region. 
Random effects models were used, which are based on the assumption that the true effect could 
vary between studies [51]. The existence of publication bias in this meta-analysis was determined 
using a funnel plot and Egger’s tests. The shape of the funnel plot in this meta-analysis showed an 
obvious symmetry, indicating the risk of publication bias is significantly low. This hypothesis was 
also supported by statistical evidence from Egger’s test (t-value = 1.24; p-value = 0.112) in which the 
publication bias did not significantly exist in this meta-analysis. Therefore, we concluded that there 
was no publication bias detected in this meta-analysis. 
Figure 5. Funnel plot of the overall lence of α-th lassem a in this study.
4. Discussion
This study is the first to report he prevale -thala semia in the Southeast Asia region over
the past 10 years (2010–2020). We did not obtai a y -thalassemia-related studies that fulfilled our
inclusion and exclusion criteria from other Southeast Asian countries, including Brunei, Indonesia,
Myanmar, Philippines, Singapore, and Timor-Leste. Using a random effects model, the overall
prevalence rate of α-thalassemia in the included countries was 22.6%, which indicated a significant
reduction of ~50% of the prevalence in the Southeast Asia region since 2008. The World Health
Organization had reported the α-thalassemia prevalence as 44.6% in 2008 [49]. India and Brazil,
were reported at about 12% and 19.2%, respectively [50,51]. The prevalence rates were high in countries
such as UAE, Oman and Saudi Arabia at 50% [52].
The h gh prevalence of α-th lassemia in the past was due to the lack of knowledge re arding
the seriousne s of th s dise se am ng the populations in these coun ries, especially t ose living in
rural areas with limited access to education and those who could not afford to obtain the proper
education similar to that found in urban areas. α-thalassemia is an inherited disease and the mutations
may pass from parent to child, affecting the haemoglobin production. Hence, the educational and
screening campaigns regarding this disease conducted by the representative bodies (either government
or non-government organization) have successfully reduced the prevalence of α-thalassemia in the
Southeast Asia region.
Random effects models were used, which are based on the assumption that the true effect could
vary between studies [51]. The existence of publication bias i this meta-analysis was determined
using a funnel plot and Egger’s tests. The shap of the funnel plot in this meta-analysis show d an
obvio s symmetry, indicating the risk of publication bias is significantly low. This hypo hesis was
also supported by statistical evidence fro Egger’s test (t-value = 1.24; p-value = 0.112) in which the
publication bias did not significantly exist in this meta-analysis. Therefore, we concluded that there
was no publication bias detected in this meta-analysis.
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When stratified according to country, Vietnam has the leading α-thalassemia prevalence rate of
51.5%. The high prevalence rate is probably due to one of the observational studies conducted in
Vietnam focusing on the country’s minority ethnic groups and thus, this likely skewed the actual
prevalence rate [51]. The prevalence of α-thalassemia in Cambodia was the second highest (39.5%)
when compared to other countries included in this meta-analysis. However, since there was only
two studies that reported the prevalence of α-thalassemia Cambodia and Vietnam, more data are
required to estimate the actual prevalence rate of this disease in both of these countries. The prevalence
of α-thalassemia in Laos, Malaysia, and Thailand was quite similar, ranging from 17.3% to 26.8%.
Alpha thalassemia is an inheritable disease where the presence of multiple deletional and non-deletional
mutations can cause severe clinical complications. The presence of α-thalassemia major causes hydrops
fetalis and prenatal deaths [4,5]. Therefore, the low prevalence of α-thalassemia in these countries
and this region indicates that genetic screening for α-thalassemia mutations in the parents could be
done in a population focused approach. Allele frequency and genetic diversity amongst the different
populations provide information that can be used effectively in designing thalassemia prevention
programs [53].
Thalassemia patients suffers from anemia caused by the imbalance of globin chains and impairment
of haemoglobin solubility of erythrocytes. The reduced globin chains were shown to impair the
cytoadherence of Plasmodium [54,55]. These abnormalities of erythrocytes have been shown to confer a
protective effect against malaria infection [12,56]. Hence, there is a natural selection pressure which
causes thalassemia becoming prevalent in countries with high incidence of malaria. Our meta-analysis
was not exhaustive, however it shows that Vietnam had the highest prevalence rate (51.5%) and the
lowest malaria cases (5794 cases) among the countries included in our study which supported the
protective factor of thalassemia [57].
There are several limitations that should be addressed in this meta-analysis. Firstly, only data
from certain Southeast Asian countries were available to be included in this meta-analysis; therefore,
the calculated α-thalassemia-related prevalence rate in this study was specific to selected Southeast
Asian regions. Besides, only studies from 2010 to 2020 were included in this meta-analysis, and it
is possible for studies published before the year 2010 that meet the inclusion criteria but were not
included in this meta-analysis, as this study focused on the prevalence rates from recent past 10 years
only. We also did not include ethnic stratification because the majority of the studies included in
this analysis did not report the ethnic group in the subject population. Alpha thalassemia genotype
stratification was not be performed due to inconsistencies in the reporting of genotypes in the studies
included in this analysis.
5. Conclusions
This is the first meta-analysis that investigated α-thalassemia prevalence in Southeast Asian
countries, and the findings suggest high prevalence of α-thalassemia events in certain countries which
warrants attention as α-thalassemia major could cause severe health complications and impose a
substantial burden to the health authority and families. The data in this meta-analysis may be beneficial
to the representative bodies in designing educational and screening campaigns regarding this disease
in order to further reduce α-thalassemia rates in these countries.
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